Furthermore, Met and NF-κB inhibitors, including bortezomib (BTZ), which is usually used for MM treatment, may also potentially mitigate MM-induced bone disease in patients expressing high levels of HGF by inhibiting osteoclast formation (Tsubaki et al., 2020). This evidence concerns the gene NFKB1 and Miyoshi myopathy.